Mark Shaw
About
Mark Shaw is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology.
According to data from OpenAlex, Mark Shaw has authored 38 papers receiving a total of 900 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 13 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Oncology. Recurrent topics in Mark Shaw's work include Renal cell carcinoma treatment (10 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Mark Shaw is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Lung Cancer Treatments and Mutations (7 papers). Mark Shaw collaborates with scholars based in Australia, United Kingdom and New Zealand. Mark Shaw's co-authors include Shankar Siva, Mathias Bressel, Tomas Kron, Sarat Chander, Nathan Lawrentschuk, Declan G. Murphy, Farshad Foroudi, Michael S. Hofman, David Ball and Jeremy Goad and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Endocrinology.
In The Last Decade
Mark Shaw
37 papers receiving 886 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Shaw Australia | 16 | 599 | 287 | 177 | 155 | 137 | 38 | 900 | ||
| Clare Griffin United Kingdom | 19 | 453 0.8× | 221 0.8× | 332 1.9× | 303 2.0× | 215 1.6× | 54 | 1.4k | ||
| Magnus Hellström Sweden | 15 | 420 0.7× | 77 0.3× | 48 0.3× | 366 2.4× | 93 0.7× | 29 | 1.2k | ||
| Michèle Tarayre France | 24 | 1.8k 3.0× | 241 0.8× | 304 1.7× | 1.4k 9.1× | 105 0.8× | 52 | 2.9k | ||
| H Nishikawa Japan | 15 | 1.2k 2.0× | 193 0.7× | 263 1.5× | 718 4.6× | 243 1.8× | 43 | 1.9k | ||
| Charlotte Baey France | 11 | 290 0.5× | 61 0.2× | 23 0.1× | 258 1.7× | 267 1.9× | 25 | 869 | ||
| Cristian Fernández-Palomo Switzerland | 20 | 494 0.8× | 489 1.7× | 356 2.0× | 107 0.7× | 15 0.1× | 45 | 881 | ||
| Christine Berger France | 12 | 207 0.3× | 77 0.3× | 68 0.4× | 434 2.8× | 418 3.1× | 31 | 842 | ||
| Greger Nilsson Sweden | 14 | 239 0.4× | 252 0.9× | 251 1.4× | 255 1.6× | 35 0.3× | 28 | 861 | ||
| Harald Hauser Germany | 14 | 138 0.2× | 327 1.1× | 21 0.1× | 279 1.8× | 30 0.2× | 22 | 741 | ||
| Melinda S. Epstein United States | 12 | 81 0.1× | 120 0.4× | 59 0.3× | 300 1.9× | 115 0.8× | 20 | 640 |
Countries citing papers authored by Mark Shaw
Since
Specialization
Citations
This map shows the geographic impact of Mark Shaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Shaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Shaw more than expected).
Fields of papers citing papers by Mark Shaw
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark Shaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Shaw. The network helps show where Mark Shaw may publish in the future.
Co-authorship network of co-authors of Mark Shaw
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Shaw. A scholar is included among the top collaborators of Mark Shaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Shaw. Mark Shaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Xie, Jing, Marliese Alexander, David W. Ball, et al.. (2025). Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study. Clinical Lung Cancer. 26(4). e311–e320.e6.
2.
Ali, Muhammad, Kendrick Koo, Daniel Moon, et al.. (2024). Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. Radiation Oncology. 19(1). 23–23.
3.
Alexander, Marliese, Jing Xie, David Ball, et al.. (2024). The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer. 190. 107531–107531.
4.
MacManus, Michael, Laura Kirby, Benjamin J. Blyth, et al.. (2023). Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC. Clinical and Translational Radiation Oncology. 43. 100682–100682.
5.
Siva, Shankar, Mathias Bressel, Mark Sidhom, et al.. (2023). TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). International Journal of Radiation Oncology*Biology*Physics. 117(2). S3–S3.
6.
Newnham, Genni M, et al.. (2023). Cancer in Victorian prisoners: a description of cancer diagnoses, demographics, risk factors and barriers to optimal care. Internal Medicine Journal. 54(2). 295–300.
7.
Siva, Shankar, Mathias Bressel, Ross Jennens, et al.. (2023). SABRSeq: A Randomized Phase Ib Trial of SABR Sequencing with Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology*Biology*Physics. 117(2). e58–e58.
8.
Siva, Shankar, Mathias Bressel, Mark Shaw, et al.. (2022). Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases. International Journal of Radiation Oncology*Biology*Physics. 114(5). 862–870.
9.
Udovicich, Cristian, Jason Callahan, Mathias Bressel, et al.. (2022). Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma. European Urology Open Science. 44. 60–68.
10.
Pryor, David, Mathias Bressel, Nathan Lawrentschuk, et al.. (2021). A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemporary Clinical Trials Communications. 21. 100703–100703.
11.
Siva, Shankar, Mathias Bressel, Simon Wood, et al.. (2021). Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. European Urology. 81(4). 364–372.
12.
Bressel, Mathias, Belinda A. Campbell, Steven David, et al.. (2020). Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis. Clinical Oncology. 33(3). 163–171.
13.
Bressel, Mathias, Steven David, Mark Shaw, et al.. (2020). Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases. International Journal of Radiation Oncology*Biology*Physics. 109(3). 756–763.
14.
Hardcastle, Nicholas, Michael S. Hofman, Ching‐Yu Lee, et al.. (2019). NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Radiation Oncology. 14(1). 164–164.
15.
Siva, Shankar, Mathias Bressel, Sherene Loi, et al.. (2019). MA01.01 Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases. Journal of Thoracic Oncology. 14(10). S248–S248.
16.
Ball, David, Gang Mai, Shalini Vinod, et al.. (2018). Quality of life in the CHISEL randomized trial of stereotactic ablative radiotherapy (SABR) versus standard radiotherapy for stage I non-small cell lung cancer (Trans-Tasman Radiation Oncology Group 09.02). Annals of Oncology. 29. ix139–ix139.
17.
Siva, Shankar, Mathias Bressel, Declan G. Murphy, et al.. (2018). Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. European Urology. 74(4). 455–462.
18.
Reynolds, Hayley M., Mary E. Finnegan, Eddie Lau, et al.. (2018). Assessing DCE-MRI and DWI as treatment response biomarkers after SABR for primary renal cell carcinoma.. Journal of Clinical Oncology. 36(15_suppl). e16587–e16587.
19.
Siva, Shankar, Price Jackson, Tomas Kron, et al.. (2016). Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose–response relationship. Radiotherapy and Oncology. 118(3). 540–546.
20.
Siva, Shankar, Nicholas Hardcastle, Tomas Kron, et al.. (2015). Ventilation/Perfusion Positron Emission Tomography—Based Assessment of Radiation Injury to Lung. International Journal of Radiation Oncology*Biology*Physics. 93(2). 408–417.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Clare Griffin Breakdown of academic impact, for papers by Magnus Hellström Breakdown of academic impact, for papers by Michèle Tarayre Breakdown of academic impact, for papers by H Nishikawa Breakdown of academic impact, for papers by Charlotte Baey Breakdown of academic impact, for papers by Cristian Fernández-Palomo Breakdown of academic impact, for papers by Christine Berger Breakdown of academic impact, for papers by Greger Nilsson Breakdown of academic impact, for papers by Harald Hauser Breakdown of academic impact, for papers by Melinda S. Epstein